Stock Events

Stock Events

Keros Therapeutics 

$11.30
27
+$0.19+1.71% 17:15 Today

Statistics

Day High
11.27
Day Low
11.17
52W High
22.55
52W Low
9.69
Volume
220
Avg. Volume
-
Mkt Cap
224.05M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.45
0.24
1.93
3.62
Expected EPS
-0.9396
Actual EPS
N/A

Financials

35.65%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
244.06MRevenue
87.01MNet Income

Analyst Ratings

20.50Average Price Target
The highest estimate is 23.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow KROS. It's not an investment recommendation.
Amazon
3
AMZN
General Motors Company
3
GM
Trade Desk
3
TTD
AeroVironment
3
AVAV

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Galmed Pharmaceuticals
GLMD
Mkt Cap4.34M
Galmed Pharmaceuticals is involved in the development of oral therapies for the treatment of liver diseases and fibrosis, competing with Keros in the fibrotic disease treatment market.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is focused on the development of gene-based therapies for serious diseases, including blood disorders, competing with Keros in the gene therapy and hematology fields.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is known for its work in treating cystic fibrosis and other serious diseases, including blood disorders, making it a competitor in the broader therapeutic market that Keros operates in.
Novartis
NVS
Mkt Cap292.35B
Novartis is a large pharmaceutical company with a broad portfolio that includes treatments for blood disorders, competing with Keros Therapeutics on a global scale.
AMGEN
AMGN
Mkt Cap233.78B
Amgen is a biotechnology giant with a wide range of products for various diseases, including those in Keros Therapeutics' areas of focus, making them a competitor in the biopharmaceutical market.

About

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Show more...
CEO
Jasbir S. Seehra
Employees
92
Country
United States
ISIN
US4923271013

Listings

XNAS
US
KROS
BOATS
BOATS
KROS.BOATS

0 Comments

Share your thoughts

FAQ

What is Keros Therapeutics stock price today?▼
The current price of KROS is $11.30 USD — it has increased by +1.71% in the past 24 hours. Watch Keros Therapeutics stock price performance more closely on the chart.
What is Keros Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Keros Therapeutics stocks are traded under the ticker KROS.
Is Keros Therapeutics stock price growing?▼
KROS stock has risen by +2.18% compared to the previous week, the month change is a +9.95% rise, over the last year Keros Therapeutics has showed a -27.52% decrease.
What is Keros Therapeutics market cap?▼
Today Keros Therapeutics has the market capitalization of 224.05M
When is the next Keros Therapeutics earnings date?▼
Keros Therapeutics is going to release the next earnings report on November 11, 2026.
What were Keros Therapeutics earnings last quarter?▼
KROS earnings for the last quarter are -1.45 USD per share, whereas the estimation was -1.34 USD resulting in a -8.21% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Keros Therapeutics revenue for the last year?▼
Keros Therapeutics revenue for the last year amounts to 244.06M USD.
What is Keros Therapeutics net income for the last year?▼
KROS net income for the last year is 87.01M USD.
How many employees does Keros Therapeutics have?▼
As of September 04, 2026, the company has 92 employees.
In which sector is Keros Therapeutics located?▼
Keros Therapeutics operates in the Health & Wellness sector.
When did Keros Therapeutics complete a stock split?▼
Keros Therapeutics has not had any recent stock splits.
Where is Keros Therapeutics headquartered?▼
Keros Therapeutics is headquartered in LEXINGTON, United States.